Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-ranging study of baricitinib in diabetic kidney disease
jRCT2080221976Phase 2Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2012
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of baricitinib in diabetic glomerulosclerosis and type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Eli Lilly and Company. Started Dec 2012; status: recruiting.
02
Drugs
baricitinib
03
Conditions
diabetic glomerulosclerosistype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2080221976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221976.